AI & Machine Learning

Carlsmed's AI-driven aprevo® platform shows massive surgeon adoption and market growth, signaling a new era of personalized, cost-effective spine care.

The Nashville hot chicken giant appoints a new franchise VP to manage its explosive growth, targeting Europe, Asia, and non-traditional US locations.

The supply chain tech leader appoints a seasoned marketing exec from Drift and Salesforce to accelerate its next growth phase and amplify its AI strategy.

The EdTech giant is unveiling an integrated ecosystem with new AI capabilities and a Microsoft Teams solution at five major international trade shows.

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.

Retailers are losing billions to refund abuse, but new AI tools can spot fraud in real time, protecting revenue without punishing your best customers.

ConcertAI and Foundation Medicine unite to create a huge dataset of 500k patients, using AI to accelerate the hunt for new life-saving cancer drugs.

A major new partnership is racing to deploy predictive tech, from blood tests to eye scans, to prevent millions of stillbirths in years, not decades.

The insurance giant landed a major credit facility, calming investor nerves and doubling down on its fast-growing pharmacy and healthcare services arm.

With preliminary Q1 revenue of $103.7M, Twist Bioscience beats forecasts, setting a bullish tone ahead of its full earnings report on February 2nd.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

With a $30M Series A from Five Elms Capital, Trybe is set to revolutionize the spa and leisure industry with AI, challenging legacy systems worldwide.

Digi International's new turnkey solution lets MSPs offer enterprise-grade 5G connectivity and recurring revenue without the upfront cost or complexity.

A new White House executive order and a proposed $1.5T budget are shaking up defense contracting. Here's how agile firms like Volatus are set to win.

A new podcast season peeks inside the minds of the ultra-wealthy as they navigate the complex, often existential, questions that follow massive success.

Annexon is poised for a landmark year with potential first-in-class drugs for GBS and GA, promising to reset treatment standards and offer new hope.

WindRose and Francisco Partners invest in Avalon, signaling a major shift toward tech-driven management of the multi-billion dollar diagnostic testing market.

BioXcel Therapeutics is pushing its drug IGALMI® for home use, a move that could transform mental healthcare but carries significant financial and safety risks.

Princeton-based EDETEK will present its AI-powered clinical trial ecosystem at the J.P. Morgan conference, aiming to capture a slice of a booming market.

The firm gives bondholders more time to trade near-term notes for a higher yield, sparking debate on strategy versus necessity in a tough market.